statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for FOLD
 DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jan 2022SVB LeerinkUpgradesMarket PerformOutperform Jan 2022Cantor FitzgeraldMaintainsOverweight
 View More...

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) shares fell 2.5% on Thursday . The company traded as low as $11.56 and last traded at $11.56. 79,464 shares traded hands during trading, a...

Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5%

A month has gone by since the last earnings report for Amicus Therapeutics (FOLD). Shares have lost about 8.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

This is a signal that FOLD's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Amicus Therapeutics (FOLD, $11.87) Stochastic Oscillator left the oversold zone on March 27, 2024

WuXi Biologics Reports Solid 2023 Annual Results WuXi Biologics Reports Solid 2023 Annual Results PR Newswire HONG KONG, March 26, 2024 Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross...

WuXi Biologics Reports Solid 2023 Annual Results

Amicus Therapeutics, Inc. (NASDAQ:FOLD  Free Report)  Research analysts at Zacks Research lifted their Q1 2024 earnings estimates for Amicus Therapeutics in a report issued on...

Zacks Research Weighs in on Amicus Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:FOLD)

Amicus Therapeutics (FOLD, $11.69) Stochastic Oscillator left the oversold zone on March 21, 2024

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines...

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

This is a signal that FOLD's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Amicus Therapeutics (FOLD, $11.81) RSI Indicator left the oversold zone on March 13, 2024

Amicus Therapeutics (FOLD, $12.29) Stochastic Oscillator left the oversold zone on March 07, 2024

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Watchers	6,238
52-Wk Low	$9.02
52-Wk High	$14.57

Volume	1.34M
52-Wk High	$14.57
52-Wk Low	$9.02

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.05	--	--	N/A
Q1'24	-$0.06	-$0.16	-148.47%	MISSED
Q4'23	-$0.06	-$0.11	-91.05%	MISSED
Q3'23	-$0.08	-$0.07	7.76%	BEAT
Q2'23	-$0.11	-$0.15	-31.64%	MISSED

FOLD Amicus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals